Bicycle Therapeutics (BCYC) Financials

$8.53 +0.33 (+3.99%)

As of 12:59 PM Eastern

Annual Income Statements for Bicycle Therapeutics

This table shows Bicycle Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-169	-181	-113
Consolidated Net Income / (Loss)	-169	-181	-113
Net Income / (Loss) Continuing Operations	-169	-181	-113
Total Pre-Tax Income	-174	-179	-114
Total Operating Income	-210	-190	-117
Total Gross Profit	35	27	14
Total Revenue	35	27	14
Operating Revenue	35	27	14
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	245	217	131
Selling, General & Admin Expense	72	60	50
Research & Development Expense	173	156	82
Total Other Income / (Expense), net	36	11	2.41
Interest Expense	2.68	3.26	3.34
Interest & Investment Income	34	14	5.76
Other Income / (Expense), net	4.48	0.00	0.00
Income Tax Expense	-4.77	1.46	-1.52
Basic Earnings per Share	($2.90)	($5.08)	($3.80)
Weighted Average Basic Shares Outstanding	58.21M	35.59M	29.66M
Diluted Earnings per Share	($2.90)	($5.08)	($3.80)
Weighted Average Diluted Shares Outstanding	58.21M	35.59M	29.66M
Weighted Average Basic & Diluted Shares Outstanding	69.20M	42.59M	30.02M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00

This table shows Bicycle Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-50	-53	-40	-27	-53	-46	-43	-39	-30	-28
Consolidated Net Income / (Loss)	-52	-51	-40	-27	-49	-50	-43	-39	-30	-28
Net Income / (Loss) Continuing Operations	-52	-51	-40	-27	-49	-50	-43	-39	-30	-28
Total Pre-Tax Income	-53	-54	-40	-27	-49	-48	-43	-40	-30	-29
Total Operating Income	-68	-64	-47	-32	-54	-51	-43	-42	-32	-30
Total Gross Profit	3.71	2.68	9.36	20	5.33	5.35	11	4.90	3.19	3.04
Total Revenue	3.71	2.68	9.36	20	5.33	5.35	11	4.90	3.19	3.04
Operating Revenue	3.71	2.68	9.36	20	5.33	5.35	11	4.90	3.19	3.04
Total Operating Expenses	71	67	56	51	60	56	55	47	35	33
Selling, General & Admin Expense	22	18	16	16	15	16	15	14	11	10
Research & Development Expense	50	48	40	35	45	40	40	32	25	23
Total Other Income / (Expense), net	15	9.60	6.95	4.80	5.47	3.17	-0.02	2.12	1.79	1.17
Interest Expense	0.05	0.99	0.82	0.82	0.82	0.81	0.82	0.81	0.83	0.82
Interest & Investment Income	10	11	7.77	5.62	6.28	3.99	0.81	2.93	2.64	1.99
Income Tax Expense	-1.08	-3.45	0.12	-0.35	0.32	2.27	-0.52	-0.62	-0.42	-0.24
Basic Earnings per Share	($0.77)	($0.74)	($0.77)	($0.62)	($1.11)	($1.26)	($1.41)	($1.30)	($1.01)	($0.96)
Weighted Average Basic Shares Outstanding	58.21M	68.99M	51.99M	42.56M	35.59M	39.58M	30.19M	30.00M	29.66M	29.68M
Diluted Earnings per Share	($0.77)	($0.74)	($0.77)	($0.62)	($1.11)	($1.26)	($1.41)	($1.30)	($1.01)	($0.96)
Weighted Average Diluted Shares Outstanding	58.21M	68.99M	51.99M	42.56M	35.59M	39.58M	30.19M	30.00M	29.66M	29.68M
Weighted Average Basic & Diluted Shares Outstanding	69.20M	69.05M	68.99M	42.78M	42.59M	42.42M	41.42M	30.04M	30.02M	29.69M

This table details how cash moves in and out of Bicycle Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	353	188	-100
Net Cash From Operating Activities	-165	-61	-86
Net Cash From Continuing Operating Activities	-165	-61	-86
Net Income / (Loss) Continuing Operations	-169	-181	-113
Consolidated Net Income / (Loss)	-169	-181	-113
Depreciation Expense	7.17	6.55	3.69
Non-Cash Adjustments To Reconcile Net Income	28	34	20
Changes in Operating Assets and Liabilities, net	-31	79	2.71
Net Cash From Investing Activities	-1.24	-2.93	-19
Net Cash From Continuing Investing Activities	-1.24	-2.93	-19
Purchase of Property, Plant & Equipment	-1.24	-2.93	-19
Net Cash From Financing Activities	520	250	6.69
Net Cash From Continuing Financing Activities	520	250	6.69
Repayment of Debt	-32	0.00	0.00
Issuance of Common Equity	544	249	5.70
Other Financing Activities, net	7.53	0.68	0.99
Effect of Exchange Rate Changes	-0.69	1.35	-1.12
Cash Interest Paid	1.40	2.75	2.79
Cash Income Taxes Paid	0.79	0.56	2.23

This table details how cash moves in and out of Bicycle Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-11	-71	504	-69	-46	232	47	-45	-22	-11
Net Cash From Operating Activities	-9.40	-40	-45	-71	-47	-1.03	34	-46	-30	-5.87
Net Cash From Continuing Operating Activities	-9.40	-40	-45	-71	-47	-1.03	34	-46	-30	-5.87
Net Income / (Loss) Continuing Operations	-52	-51	-40	-27	-49	-50	-43	-39	-30	-28
Consolidated Net Income / (Loss)	-52	-51	-40	-27	-49	-50	-43	-39	-30	-28
Depreciation Expense	1.70	2.17	1.64	1.66	1.65	1.69	1.65	1.56	1.39	1.26
Non-Cash Adjustments To Reconcile Net Income	26	3.80	3.93	-5.56	3.76	3.58	25	1.22	1.68	7.90
Changes in Operating Assets and Liabilities, net	15	5.00	-10	-40	-3.60	44	50	-10	-3.40	13
Net Cash From Investing Activities	-0.37	-0.44	-0.42	-0.01	-0.05	-0.50	-0.28	-2.10	-1.45	-2.98
Net Cash From Continuing Investing Activities	-0.37	-0.44	-0.42	-0.01	-0.05	-0.50	-0.28	-2.10	-1.45	-2.98
Purchase of Property, Plant & Equipment	-0.37	-0.44	-0.42	-0.01	-0.05	-0.50	-0.28	-2.10	-1.45	-2.98
Net Cash From Financing Activities	0.20	-32	550	1.87	0.39	235	12	2.72	5.89	0.16
Net Cash From Continuing Financing Activities	0.20	-32	550	1.87	0.39	235	12	2.72	5.89	0.16
Repayment of Debt	-0.04	-	-	-	-	-	-	-	-	-
Other Financing Activities, net	0.25	0.91	4.50	1.87	0.38	0.14	0.17	0.00	0.19	0.16
Effect of Exchange Rate Changes	-1.78	1.70	-0.19	-0.42	1.29	-0.90	0.51	0.45	3.55	-2.60
Cash Interest Paid	0.02	0.23	0.46	0.69	0.69	0.69	0.69	0.68	0.69	0.71

This table presents Bicycle Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	957	595	411
Total Current Assets	929	562	369
Cash & Equivalents	880	526	339
Prepaid Expenses	13	11	9.02
Other Current Assets	36	24	19
Plant, Property, & Equipment, net	9.52	15	19
Total Noncurrent Assets	19	19	22
Other Noncurrent Operating Assets	19	19	22
Total Liabilities & Shareholders' Equity	957	595	411
Total Liabilities	164	224	140
Total Current Liabilities	67	70	53
Accounts Payable	16	13	6.47
Accrued Expenses	41	32	26
Current Deferred Revenue	10	25	20
Total Noncurrent Liabilities	97	155	86
Long-Term Debt	0.00	31	30
Noncurrent Deferred Revenue	91	110	41
Other Noncurrent Operating Liabilities	5.11	14	15
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	793	371	271
Total Preferred & Common Equity	793	371	271
Total Common Equity	793	371	271
Common Stock	1,474	884	601
Retained Earnings	-681	-512	-331
Accumulated Other Comprehensive Income / (Loss)	0.12	-1.30	0.39

This table presents Bicycle Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	997	1,057	547	639	454	429	417
Total Current Assets	966	1,028	516	603	408	381	381
Cash & Equivalents	891	961	457	572	340	294	361
Prepaid Expenses	17	20	20	14	10	11	8.45
Other Current Assets	58	46	39	17	13	27	11
Plant, Property, & Equipment, net	12	12	13	16	18	18	16
Total Noncurrent Assets	19	18	18	20	28	29	20
Other Noncurrent Operating Assets	19	18	18	20	28	29	20
Total Liabilities & Shareholders' Equity	997	1,057	547	639	454	429	417
Total Liabilities	166	184	191	223	234	186	128
Total Current Liabilities	56	70	50	70	72	53	42
Accounts Payable	5.71	7.45	7.06	8.49	5.25	2.81	7.06
Accrued Expenses	39	28	26	34	37	25	18
Current Deferred Revenue	11	12	16	27	30	25	16
Total Noncurrent Liabilities	109	114	142	153	162	133	86
Long-Term Debt	0.00	8.51	31	31	31	30	30
Noncurrent Deferred Revenue	98	94	98	108	115	84	42
Other Noncurrent Operating Liabilities	11	11	13	15	16	18	14
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	831	874	356	416	220	243	289
Total Preferred & Common Equity	831	874	356	416	220	243	289
Total Common Equity	831	874	356	416	220	243	289
Common Stock	1,463	1,453	895	876	634	613	590
Retained Earnings	-629	-578	-538	-463	-413	-370	-301
Accumulated Other Comprehensive Income / (Loss)	-3.19	-1.09	-0.78	2.89	-0.88	0.07	0.53

This table displays calculated financial ratios and metrics derived from Bicycle Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	30.76%	86.52%	23.65%
EBITDA Growth	-8.08%	-62.35%	-75.93%
EBIT Growth	-8.13%	-62.83%	-77.78%
NOPAT Growth	-10.49%	-62.83%	-77.78%
Net Income Growth	6.44%	-60.28%	-68.69%
EPS Growth	42.91%	-33.68%	-42.32%
Operating Cash Flow Growth	-171.70%	29.59%	-482.07%
Free Cash Flow Firm Growth	-300.74%	56.45%	-1,028.75%
Invested Capital Growth	30.72%	-227.92%	39.16%
Revenue Q/Q Growth	-4.40%	8.64%	-3.89%
EBITDA Q/Q Growth	-4.70%	-13.46%	-13.24%
EBIT Q/Q Growth	-4.56%	-13.12%	-13.85%
NOPAT Q/Q Growth	-6.84%	-13.12%	-13.85%
Net Income Q/Q Growth	-1.66%	-11.84%	-11.85%
EPS Q/Q Growth	10.49%	-2.01%	-11.76%
Operating Cash Flow Q/Q Growth	18.70%	-38.90%	-30.00%
Free Cash Flow Firm Q/Q Growth	8.81%	-36.57%	-19.39%
Invested Capital Q/Q Growth	-44.51%	0.53%	8.88%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-561.93%	-679.86%	-781.06%
Operating Margin	-594.96%	-704.13%	-806.56%
EBIT Margin	-582.27%	-704.13%	-806.56%
Profit (Net Income) Margin	-479.18%	-669.72%	-779.35%
Tax Burden Percent	97.26%	100.81%	98.67%
Interest Burden Percent	84.62%	94.35%	97.93%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-29.04%	-56.31%	-36.53%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-26.46%	-37.76%	-26.20%
Return on Assets (ROA)	-21.78%	-35.92%	-25.32%
Return on Common Equity (ROCE)	-29.04%	-56.31%	-36.53%
Return on Equity Simple (ROE_SIMPLE)	-21.31%	-48.71%	-41.63%
Net Operating Profit after Tax (NOPAT)	-147	-133	-82
NOPAT Margin	-416.47%	-492.89%	-564.59%
Net Nonoperating Expense Percent (NNEP)	-3.22%	-11.86%	-8.66%
Return On Investment Capital (ROIC_SIMPLE)	-18.52%	-33.11%	-27.12%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	204.62%	224.00%	342.30%
R&D to Revenue	490.34%	580.13%	564.26%
Operating Expenses to Revenue	694.96%	804.13%	906.56%
Earnings before Interest and Taxes (EBIT)	-205	-190	-117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-198	-183	-113
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.22	2.07	3.25
Price to Tangible Book Value (P/TBV)	1.22	2.07	3.25
Price to Revenue (P/Rev)	27.40	28.43	60.76
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.47	10.06	39.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.08	0.11
Long-Term Debt to Equity	0.00	0.08	0.11
Financial Leverage	-1.18	-1.25	-1.16
Leverage Ratio	1.33	1.57	1.44
Compound Leverage Factor	1.13	1.48	1.41
Debt to Total Capital	0.00%	7.64%	10.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	7.64%	10.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	92.36%	89.93%
Debt to EBITDA	0.00	-0.17	-0.27
Net Debt to EBITDA	0.00	2.70	2.73
Long-Term Debt to EBITDA	0.00	-0.17	-0.27
Debt to NOPAT	0.00	-0.23	-0.37
Net Debt to NOPAT	0.00	3.73	3.78
Long-Term Debt to NOPAT	0.00	-0.23	-0.37
Altman Z-Score	2.95	0.83	2.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	13.81	8.08	6.92
Quick Ratio	13.08	7.57	6.40
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-185	-46	-106
Operating Cash Flow to CapEx	-13,337.98%	-2,069.92%	-453.53%
Free Cash Flow to Firm to Interest Expense	-69.02	-14.17	-31.74
Operating Cash Flow to Interest Expense	-61.37	-18.58	-25.75
Operating Cash Flow Less CapEx to Interest Expense	-61.83	-19.48	-31.43
Efficiency Ratios	-	-	-
Asset Turnover	0.05	0.05	0.03
Accounts Receivable Turnover	0.00	0.00	9.50
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.94	1.60	1.30
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	38.42
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	38.42
Capital & Investment Metrics	-	-	-
Invested Capital	-86	-125	-38
Invested Capital Turnover	-0.33	-0.33	-0.29
Increase / (Decrease) in Invested Capital	38	-87	24
Enterprise Value (EV)	87	271	570
Market Capitalization	967	767	879
Book Value per Share	$11.49	$8.74	$9.12
Tangible Book Value per Share	$11.49	$8.74	$9.12
Total Capital	793	402	301
Total Debt	0.00	31	30
Total Long-Term Debt	0.00	31	30
Net Debt	-880	-496	-309
Capital Expenditures (CapEx)	1.24	2.93	19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-34	-23
Debt-free Net Working Capital (DFNWC)	861	492	316
Net Working Capital (NWC)	861	492	316
Net Nonoperating Expense (NNE)	22	48	31
Net Nonoperating Obligations (NNO)	-880	-496	-309
Total Depreciation and Amortization (D&A)	7.17	6.55	3.69
Debt-free, Cash-free Net Working Capital to Revenue	-51.44%	-126.38%	-159.81%
Debt-free Net Working Capital to Revenue	2,441.89%	1,825.07%	2,185.17%
Net Working Capital to Revenue	2,441.89%	1,825.07%	2,185.17%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.90)	($5.08)	($3.80)
Adjusted Weighted Average Basic Shares Outstanding	58.21M	35.59M	29.66M
Adjusted Diluted Earnings per Share	($2.90)	($5.08)	($3.80)
Adjusted Weighted Average Diluted Shares Outstanding	58.21M	35.59M	29.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.20M	42.59M	30.02M
Normalized Net Operating Profit after Tax (NOPAT)	-147	-133	-82
Normalized NOPAT Margin	-416.47%	-492.89%	-564.59%
Pre Tax Income Margin	-492.69%	-664.32%	-789.88%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-76.53	-58.21	-34.88
NOPAT to Interest Expense	-54.74	-40.75	-24.42
EBIT Less CapEx to Interest Expense	-76.99	-59.11	-40.56
NOPAT Less CapEx to Interest Expense	-55.20	-41.65	-30.10
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Bicycle Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-30.44%	-50.00%	-17.86%	298.90%	67.38%	76.05%	160.32%	26.84%	-15.54%	-29.84%
EBITDA Growth	-25.44%	-25.59%	-8.52%	25.31%	-70.58%	-72.34%	-55.58%	-49.27%	-74.98%	-104.16%
EBIT Growth	-24.76%	-25.69%	-8.18%	24.13%	-68.37%	-70.69%	-58.09%	-52.66%	-78.72%	-108.19%
NOPAT Growth	-24.76%	-25.69%	-8.20%	24.13%	-68.37%	-70.69%	-57.92%	-52.66%	-78.72%	-108.19%
Net Income Growth	-5.61%	-1.81%	6.55%	32.00%	-63.78%	-76.03%	-58.80%	-41.72%	-66.20%	-93.13%
EPS Growth	30.63%	41.27%	45.39%	52.31%	-9.90%	-31.25%	-56.67%	-39.78%	-65.57%	-62.71%
Operating Cash Flow Growth	80.13%	-3,786.05%	-230.89%	-52.70%	-56.02%	82.54%	244.90%	-75.80%	-190.46%	-127.03%
Free Cash Flow Firm Growth	-275.71%	-329.17%	-331.71%	149.37%	203.67%	226.63%	290.21%	-1,648.51%	-296.74%	-264.73%
Invested Capital Growth	30.72%	52.31%	36.94%	-246.66%	-227.92%	-200.41%	-187.59%	57.04%	39.16%	29.15%
Revenue Q/Q Growth	38.57%	-71.41%	-52.07%	266.35%	-0.39%	-53.04%	132.78%	53.72%	4.77%	-30.56%
EBITDA Q/Q Growth	-6.95%	-37.03%	-49.73%	42.83%	-7.07%	-18.40%	-3.05%	-30.56%	-8.18%	-6.89%
EBIT Q/Q Growth	-5.98%	-36.87%	-47.08%	41.52%	-6.77%	-17.80%	-3.15%	-29.78%	-8.24%	-9.11%
NOPAT Q/Q Growth	-5.98%	-36.87%	-47.08%	41.52%	-6.77%	-17.83%	-3.13%	-29.78%	-8.24%	-9.01%
Net Income Q/Q Growth	-2.07%	-27.60%	-49.88%	45.90%	1.60%	-17.12%	-9.06%	-30.31%	-5.75%	-5.66%
EPS Q/Q Growth	-4.05%	3.90%	-24.19%	44.14%	11.90%	10.64%	-8.46%	-28.71%	-5.21%	-6.67%
Operating Cash Flow Q/Q Growth	76.41%	10.74%	37.03%	-49.87%	-4,513.46%	-103.01%	173.47%	-53.13%	-416.25%	75.05%
Free Cash Flow Firm Q/Q Growth	22.32%	-67.58%	-337.57%	-43.18%	1.32%	69.43%	150.62%	-19.32%	-23.75%	-154.51%
Invested Capital Q/Q Growth	-44.51%	-5.63%	19.25%	43.79%	0.53%	-39.67%	-343.90%	46.83%	8.88%	-33.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-1,778.83%	-2,304.71%	-480.79%	-153.91%	-986.33%	-917.54%	-363.91%	-822.02%	-967.82%	-937.34%
Operating Margin	-1,824.78%	-2,385.87%	-498.31%	-162.40%	-1,017.35%	-949.12%	-378.27%	-853.82%	-1,011.33%	-978.91%
EBIT Margin	-1,824.78%	-2,385.87%	-498.31%	-162.40%	-1,017.35%	-949.12%	-378.35%	-853.82%	-1,011.33%	-978.91%
Profit (Net Income) Margin	-1,398.44%	-1,898.43%	-425.30%	-136.01%	-921.01%	-932.32%	-373.81%	-797.88%	-941.22%	-932.47%
Tax Burden Percent	97.96%	93.64%	100.29%	98.70%	100.66%	104.77%	98.80%	98.44%	98.62%	99.17%
Interest Burden Percent	78.23%	84.97%	85.10%	84.86%	89.94%	93.76%	100.00%	94.93%	94.37%	96.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-29.04%	-26.67%	-30.24%	-56.13%	-56.31%	-45.80%	-52.68%	-43.32%	-36.53%	-43.79%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-82.94%	-107.66%	-26.09%	-13.85%	-54.56%	-44.64%	-18.94%	-29.79%	-32.85%	-42.18%
Return on Assets (ROA)	-63.56%	-85.66%	-22.27%	-11.60%	-49.40%	-43.85%	-18.71%	-27.84%	-30.58%	-40.18%
Return on Common Equity (ROCE)	-29.04%	-26.67%	-30.24%	-56.13%	-56.31%	-45.80%	-52.68%	-43.32%	-36.53%	-43.79%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-20.01%	-18.93%	-47.23%	0.00%	-38.83%	-63.60%	-51.08%	0.00%	-34.81%
Net Operating Profit after Tax (NOPAT)	-47	-45	-33	-22	-38	-36	-30	-29	-23	-21
NOPAT Margin	-1,277.35%	-1,670.11%	-348.82%	-113.68%	-712.15%	-664.39%	-264.79%	-597.67%	-707.93%	-685.24%
Net Nonoperating Expense Percent (NNEP)	-0.65%	-0.85%	-1.15%	-1.27%	-2.77%	-3.29%	-3.81%	-3.06%	-2.07%	-2.68%
Return On Investment Capital (ROIC_SIMPLE)	-5.97%	-	-	-	-9.45%	-	-	-	-7.49%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	582.34%	682.25%	170.38%	83.88%	278.92%	304.20%	129.75%	295.92%	335.23%	330.49%
R&D to Revenue	1,342.45%	1,803.62%	427.94%	178.52%	838.44%	744.92%	348.51%	657.90%	776.11%	748.42%
Operating Expenses to Revenue	1,924.78%	2,485.87%	598.31%	262.40%	1,117.35%	1,049.12%	478.27%	953.82%	1,111.33%	1,078.91%
Earnings before Interest and Taxes (EBIT)	-68	-64	-47	-32	-54	-51	-43	-42	-32	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-66	-62	-45	-30	-53	-49	-41	-40	-31	-28
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.22	1.88	0.99	2.97	2.07	2.00	3.48	2.63	3.25	2.38
Price to Tangible Book Value (P/TBV)	1.22	1.88	0.99	2.97	2.07	2.00	3.48	2.63	3.25	2.38
Price to Revenue (P/Rev)	27.40	42.31	21.88	25.39	28.43	33.51	34.05	41.20	60.76	45.87
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.47	18.17	0.00	15.14	10.06	11.71	20.29	24.20	39.41	23.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.04	0.09	0.08	0.07	0.14	0.13	0.11	0.10
Long-Term Debt to Equity	0.00	0.00	0.01	0.09	0.08	0.07	0.14	0.13	0.11	0.10
Financial Leverage	-1.18	-1.15	-1.13	-1.15	-1.25	-1.24	-1.23	-1.12	-1.16	-1.22
Leverage Ratio	1.33	1.31	1.38	1.63	1.57	1.50	1.69	1.55	1.44	1.52
Compound Leverage Factor	1.04	1.11	1.18	1.38	1.41	1.40	1.69	1.47	1.36	1.46
Debt to Total Capital	0.00%	0.00%	3.42%	7.96%	7.64%	6.85%	12.18%	11.12%	10.07%	9.46%
Short-Term Debt to Total Capital	0.00%	0.00%	2.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.94%	7.96%	7.64%	6.85%	12.18%	11.12%	10.07%	9.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	96.58%	92.04%	92.36%	93.15%	87.82%	88.88%	89.93%	90.54%
Debt to EBITDA	0.00	0.00	-0.17	-0.18	-0.17	-0.19	-0.22	-0.24	-0.27	-0.30
Net Debt to EBITDA	0.00	0.00	5.26	2.46	2.70	3.35	2.20	2.09	2.73	3.32
Long-Term Debt to EBITDA	0.00	0.00	-0.05	-0.18	-0.17	-0.19	-0.22	-0.24	-0.27	-0.30
Debt to NOPAT	0.00	0.00	-0.24	-0.24	-0.23	-0.26	-0.30	-0.33	-0.37	-0.42
Net Debt to NOPAT	0.00	0.00	7.25	3.39	3.73	4.61	3.01	2.87	3.78	4.62
Long-Term Debt to NOPAT	0.00	0.00	-0.07	-0.24	-0.23	-0.26	-0.30	-0.33	-0.37	-0.42
Altman Z-Score	3.43	5.69	3.04	2.85	1.58	2.01	1.32	1.49	3.34	3.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	13.81	17.13	14.77	10.42	8.08	8.65	5.65	7.19	6.92	9.18
Quick Ratio	13.08	15.79	13.81	9.23	7.57	8.20	5.33	6.49	6.40	8.70
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-86	-110	-66	28	49	48	28	-56	-47	-38
Operating Cash Flow to CapEx	-2,553.26%	-9,156.78%	-10,625.48%	-590,575.00%	-92,721.57%	-204.18%	12,309.03%	-2,211.10%	-2,093.16%	-196.75%
Free Cash Flow to Firm to Interest Expense	-1,648.02	-111.78	-79.90	33.75	59.48	59.14	34.61	-69.47	-56.95	-46.53
Operating Cash Flow to Interest Expense	-180.69	-40.36	-54.16	-86.32	-57.67	-1.26	41.53	-57.44	-36.69	-7.19
Operating Cash Flow Less CapEx to Interest Expense	-187.77	-40.80	-54.67	-86.34	-57.73	-1.88	41.19	-60.04	-38.45	-10.84
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.05	0.05	0.05	0.09	0.05	0.05	0.05	0.03	0.03	0.04
Accounts Receivable Turnover	0.00	0.00	1.75	0.00	0.00	0.00	0.82	0.00	9.50	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.94	2.72	2.71	2.68	1.60	1.56	1.31	1.14	1.30	1.61
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	209.01	0.00	0.00	0.00	446.48	0.00	38.42	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	209.01	0.00	0.00	0.00	446.48	0.00	38.42	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-86	-60	-57	-70	-125	-125	-90	-20	-38	-42
Invested Capital Turnover	-0.33	-0.40	-0.54	-0.92	-0.33	-0.30	-0.37	-0.46	-0.29	-0.30
Increase / (Decrease) in Invested Capital	38	66	33	-50	-87	-84	-59	27	24	17
Enterprise Value (EV)	87	670	-65	630	271	291	457	375	570	359
Market Capitalization	967	1,561	866	1,056	767	832	767	639	879	690
Book Value per Share	$11.49	$12.05	$20.43	$8.37	$8.74	$10.04	$7.33	$8.10	$9.12	$9.75
Tangible Book Value per Share	$11.49	$12.05	$20.43	$8.37	$8.74	$10.04	$7.33	$8.10	$9.12	$9.75
Total Capital	793	831	905	387	402	447	251	274	301	320
Total Debt	0.00	0.00	31	31	31	31	31	30	30	30
Total Long-Term Debt	0.00	0.00	8.51	31	31	31	31	30	30	30
Net Debt	-880	-891	-930	-426	-496	-541	-310	-263	-309	-331
Capital Expenditures (CapEx)	0.37	0.44	0.42	0.01	0.05	0.50	0.28	2.10	1.45	2.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	19	20	9.46	-34	-39	-4.27	34	-23	-22
Debt-free Net Working Capital (DFNWC)	861	910	981	466	492	533	336	328	316	340
Net Working Capital (NWC)	861	910	959	466	492	533	336	328	316	340
Net Nonoperating Expense (NNE)	4.49	6.11	7.16	4.36	11	14	12	9.80	7.43	7.52
Net Nonoperating Obligations (NNO)	-880	-891	-930	-426	-496	-541	-310	-263	-309	-331
Total Depreciation and Amortization (D&A)	1.70	2.17	1.64	1.66	1.65	1.69	1.65	1.56	1.39	1.26
Debt-free, Cash-free Net Working Capital to Revenue	-51.44%	51.30%	49.74%	22.72%	-126.38%	-156.21%	-18.96%	222.23%	-159.81%	-144.43%
Debt-free Net Working Capital to Revenue	2,441.89%	2,465.69%	2,479.02%	1,121.01%	1,825.07%	2,147.81%	1,492.87%	2,117.93%	2,185.17%	2,257.51%
Net Working Capital to Revenue	2,441.89%	2,465.69%	2,422.41%	1,121.01%	1,825.07%	2,147.81%	1,492.87%	2,117.93%	2,185.17%	2,257.51%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.77)	($0.74)	($0.77)	($0.62)	($1.11)	($1.26)	($1.41)	($1.30)	($1.01)	($0.96)
Adjusted Weighted Average Basic Shares Outstanding	58.21M	68.99M	51.99M	42.56M	35.59M	39.58M	30.19M	30.00M	29.66M	29.68M
Adjusted Diluted Earnings per Share	($0.77)	($0.74)	($0.77)	($0.62)	($1.11)	($1.26)	($1.41)	($1.30)	($1.01)	($0.96)
Adjusted Weighted Average Diluted Shares Outstanding	58.21M	68.99M	51.99M	42.56M	35.59M	39.58M	30.19M	30.00M	29.66M	29.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.20M	69.05M	68.99M	42.78M	42.59M	42.42M	41.42M	30.04M	30.02M	29.69M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-45	-33	-22	-38	-36	-30	-29	-23	-21
Normalized NOPAT Margin	-1,277.35%	-1,670.11%	-348.82%	-113.68%	-712.15%	-664.39%	-264.79%	-597.67%	-707.93%	-685.24%
Pre Tax Income Margin	-1,427.62%	-2,027.28%	-424.07%	-137.80%	-915.01%	-889.87%	-378.35%	-810.50%	-954.41%	-940.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1,301.21	-64.69	-56.61	-38.63	-66.14	-62.40	-52.52	-51.74	-39.00	-36.42
NOPAT to Interest Expense	-910.85	-45.28	-39.63	-27.04	-46.30	-43.68	-36.76	-36.22	-27.30	-25.50
EBIT Less CapEx to Interest Expense	-1,308.29	-65.13	-57.12	-38.65	-66.20	-63.02	-52.86	-54.33	-40.75	-40.08
NOPAT Less CapEx to Interest Expense	-917.93	-45.72	-40.14	-27.06	-46.36	-44.30	-37.09	-38.81	-29.05	-29.15
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Bicycle Therapeutics' Financials

When does Bicycle Therapeutics's financial year end?

According to the most recent income statement we have on file, Bicycle Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bicycle Therapeutics' net income changed over the last 2 years?

Bicycle Therapeutics' net income appears to be on an upward trend, with a most recent value of -$169.03 million in 2024, rising from -$112.72 million in 2022. The previous period was -$180.66 million in 2023. See Bicycle Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Bicycle Therapeutics's operating income?

Bicycle Therapeutics's total operating income in 2024 was -$209.87 million, based on the following breakdown:

Total Gross Profit: $35.28 million
Total Operating Expenses: $245.15 million

How has Bicycle Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Bicycle Therapeutics' total revenue changed from $14.46 million in 2022 to $35.28 million in 2024, a change of 143.9%.

How much debt does Bicycle Therapeutics have?

Bicycle Therapeutics' total liabilities were at $163.81 million at the end of 2024, a 27.0% decrease from 2023, and a 17.2% increase since 2022.

How much cash does Bicycle Therapeutics have?

In the past 2 years, Bicycle Therapeutics' cash and equivalents has ranged from $339.15 million in 2022 to $879.52 million in 2024, and is currently $879.52 million as of their latest financial filing in 2024.

How has Bicycle Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Bicycle Therapeutics' book value per share changed from 9.12 in 2022 to 11.49 in 2024, a change of 25.9%.

Related Companies

This page (NASDAQ:BCYC) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Financials

Frequently Asked Questions About Bicycle Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Financials

Annual Income Statements for Bicycle Therapeutics

Quarterly Income Statements for Bicycle Therapeutics

Annual Cash Flow Statements for Bicycle Therapeutics

Quarterly Cash Flow Statements for Bicycle Therapeutics

Annual Balance Sheets for Bicycle Therapeutics

Quarterly Balance Sheets for Bicycle Therapeutics

Annual Metrics And Ratios for Bicycle Therapeutics

Quarterly Metrics And Ratios for Bicycle Therapeutics

Frequently Asked Questions About Bicycle Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools